Information Provided By: 
Fly News Breaks for May 28, 2019
PTCT
May 28, 2019 | 07:44 EDT
After traveling with management, Cantor Fitzgerald analyst Alethia Young says PTC Therapeutics remains a top small-mid-cap franchise pick. The company has "many realizable shots on goal" that remain unappreciated at current share levels, Young tells investors in a research note. She thinks investors assign little credit to PTC's AADC deficiency opportunity in gene therapy. Young models peak sales of $400M and a 20% probability of success. The analyst reiterates an Overweight rating on PTC Therapeutics with a $61 price target.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
